SUTRO BIOPHARMA, INC. (STRO) Current Ratio
- Current ratio · latest quarter: Value 3.32×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.32× | Current assets / current liabilities. $175.65M ÷ $52.90M ≈ 3.32× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 175.65M USD | Assets, Current |
| Current obligations | 52.90M USD | Liabilities, Current |
| Cash and equivalents | 54.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 110.01M USD | Marketable Securities, Current |
| Customer receivables | 5.80M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 3.36M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $175.65M | $52.90M | $54.34M | $110.01M | $5.80M | (m) | $3.36M | (m) | 3.32× |
| 2026-03-31 | $220.97M | $70.81M | $73.68M | $128.88M | $12.48M | (m) | $5.49M | (m) | 3.12× |
| 2025-12-31 | $150.93M | $75.13M | $58.13M | $83.30M | $3.98M | (m) | $7.57M | (m) | 2.01× |
| 2025-09-30 | $182.11M | $71.89M | $65.93M | $101.67M | $3.92M | (m) | $7.03M | (m) | 2.53× |
| 2025-06-30 | $231.63M | $74.25M | $64.03M | $141.11M | $8.00M | (m) | $4.31M | (m) | 3.12× |
| 2025-03-31 | $287.41M | $133.05M | $106.23M | $142.74M | $13.56M | (m) | $8.18M | (m) | 2.16× |
| 2024-12-31 | $343.31M | $131.89M | $190.30M | $126.59M | $8.62M | (m) | $10.47M | (m) | 2.60× |
| 2024-09-30 | $405.78M | $131.29M | $174.58M | $213.68M | $6.66M | (m) | $6.22M | (m) | 3.09× |
| 2024-06-30 | $443.48M | $129.99M | $90.79M | $284.78M | $6.95M | (m) | $6.09M | (m) | 3.41× |
| 2024-03-31 | $354.58M | $79.51M | $65.22M | $202.38M | $31.30M | (m) | $7.51M | (m) | 4.46× |
| 2023-12-31 | $421.54M | $93.75M | $69.27M | $264.41M | $36.08M | (m) | $9.44M | (m) | 4.50× |
| 2023-09-30 | $381.25M | $73.61M | $81.83M | $239.27M | $16.63M | (m) | $5.53M | (m) | 5.18× |
| 2023-06-30 | $411.99M | $67.13M | $235.09M | $123.20M | $10.00M | (m) | $3.86M | (m) | 6.14× |
| 2023-03-31 | $304.06M | $59.49M | $62.47M | $188.99M | $9.87M | (m) | $5.06M | (m) | 5.11× |
| 2022-12-31 | $353.15M | $66.55M | $47.25M | $255.09M | $7.12M | (m) | $4.80M | $12.50M | 5.31× |
| 2022-09-30 | $346.55M | $58.29M | $96.78M | $190.56M | $11.24M | (m) | $12.44M | (m) | 5.95× |
| 2022-06-30 | $331.51M | $44.57M | $79.11M | $112.51M | $97.67M | (m) | $12.57M | (m) | 7.44× |
| 2022-03-31 | $228.74M | $38.76M | $28.90M | $142.50M | $11.69M | (m) | $10.71M | (m) | 5.90× |
| 2021-12-31 | $218.51M | $41.74M | $30.41M | $130.34M | $12.45M | (m) | $6.01M | $9.38M | 5.24× |
| 2021-09-30 | $250.73M | $35.45M | $30.71M | $159.23M | $12.33M | (m) | $11.17M | (m) | 7.07× |
| 2021-06-30 | $277.62M | $26.13M | $56.39M | $167.03M | $9.16M | (m) | $7.64M | (m) | 10.63× |
| 2021-03-31 | $266.00M | $22.66M | $55.82M | $164.46M | $7.23M | (m) | $5.89M | (m) | 11.74× |
| 2020-12-31 | $378.18M | $29.60M | $206.15M | $120.34M | $5.56M | (m) | $5.54M | (m) | 12.78× |
| 2020-09-30 | $292.30M | $29.91M | $64.37M | $137.99M | $7.48M | (m) | $4.88M | (m) | 9.77× |
| 2020-06-30 | $258.49M | $35.46M | $65.35M | $136.01M | $5.10M | (m) | $4.90M | (m) | 7.29× |
| 2020-03-31 | $127.46M | $32.01M | $43.56M | $71.83M | $9.08M | (m) | $5.84M | (m) | 3.98× |
| 2019-12-31 | $128.57M | $32.97M | $4.96M | $112.90M | $6.30M | (m) | $5.58M | (m) | 3.90× |
| 2019-09-30 | $135.57M | $35.86M | $11.95M | $113.21M | $7.53M | (m) | $4.55M | (m) | 3.78× |
| 2019-06-30 | $162.22M | $36.10M | $19.39M | $133.77M | $6.50M | (m) | $4.52M | (m) | 4.49× |
| 2019-03-31 | $176.53M | $31.13M | $26.62M | $143.95M | $3.34M | (m) | $3.40M | (m) | 5.67× |
| 2018-12-31 | $209.95M | $36.42M | $125.30M | $79.19M | $2.49M | (m) | $3.06M | (m) | 5.76× |
| 2018-09-30 | $127.37M | $36.91M | $41.35M | $81.60M | $2.44M | (m) | $4.59M | (m) | 3.45× |
| 2017-12-31 | $25.63M | $31.96M | $22.02M | (m) | $1.62M | (m) | $2.90M | (m) | 0.80× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |